Appendix 4G - Corporate Governance Statement
Released
Released
Announcement PDF
Appendix 4G – Corporate Governance Statement
Melbourne, Australia; 24 August 2023: Starpharma (ASX: SPL, OTCQX: SPHRY) today
releases its Appendix 4G – Key to Disclosures Corporate Governance Council Principles
and Recommendations, in accordance with ASX Listing Rules 4.7.3 and 4.10.3.
About Starpharma
Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) is a world leader in dendrimer technology for medical applications.
As an innovative Australian biopharmaceutical company, Starpharma is focussed on developing and commercialising novel
therapeutic products that address significant global healthcare needs. Starpharma boasts a strong portfolio of products,
partnerships, and intellectual property.
Starpharma’s innovative technology is based on proprietary polymers called dendrimers, which are precise, synthetically
manufactured, nanoscale molecules. The unique properties of dendrimers – including their size, structure, high degree of
branching, polyvalency, and water solubility – are advantageous in medical and pharmaceutical applications.
Starpharma uses its dendrimer technology to develop novel therapeutics and to improve the performance of existing
pharmaceuticals. Starpharma’s portfolio includes multiple clinical-stage oncology products, which utilise its Dendrimer Enhanced
Product (‘DEP®’) drug delivery technology, and marketed products, including VIRALEZE™ and VivaGel® BV, which utilise
SPL7013, a proprietary dendrimer with antimicrobial properties.
Starpharma’s DEP® drug delivery platform is being used to enhance the effectiveness of existing and novel therapies and to
reduce drug-related toxicities through controlled and specified drug delivery.
In addition to Starpharma’s internal DEP® programs, Starpharma has multiple DEP® partnerships with international
biopharmaceutical companies, including AstraZeneca (oncology); MSD (Antibody-Drug Conjugates); Chase Sun (anti-infectives);
and other world-leading pharmaceutical companies. Due to the broad applicability and optionality of Starpharma’s DEP® platform,
partnered DEP® programs have the potential to generate significant future milestones and royalties.
Starpharma’s topical antiviral nasal spray, VIRALEZE™, is now registered in more than 35 countries*, including Europe, the UK,
and Asia. Starpharma’s novel non-antibiotic vaginal gel, VivaGel® BV, for the treatment of bacterial vaginosis (BV) and prevention
of recurrent BV, is registered in more than 50 countries, including in the UK, Europe, Southeast Asia, South Africa, Australia and
New Zealand.
For more information about Starpharma, visit www.starpharma.com or connect with Starpharma on LinkedIn.
Media: Sumit Media
Grant Titmus
Mob: +61 419 388 161
grant@sumitmedia.com.au
Forward Looking Statements
Starpharma Holdings Limited
Dr Jackie Fairley, Chief Executive Officer
Justin Cahill, CFO and Company Secretary
+61 3 8532 2704
investor.relations@starpharma.com
4-6 Southampton Crescent
Abbotsford Vic 3067
Disclosure
This ASX Announcement was
authorised for release by the
Board of Directors.
This document contains certain forward-looking statements, relating to Starpharma’s business, which can be identified by the use of forward-looking
terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set to”,
“potential”, “seeking to”, “goal”, “could provide”, “intends”, “is being developed”, “could be”, “on track”, “outlook”, or similar expressions, or by
express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forwardlooking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from
any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future
regulatory filings will satisfy the FDA’s and other authorities’ requirements regarding any one or more product candidates nor can there be any
assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of
sales. In particular, management’s expectations regarding the approval and commercialization of the product candidates could be affected by,
among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays,
or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general;
government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products,
product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.
Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking
statements contained in this document as a result of new information, future events or developments or otherwise. Clinical case studies and other
clinical information given in this document are given for illustrative purposes only and are not necessarily a guide to product performance and no
representation or warranty is made by any person as to the likelihood of achievement or reasonableness of future results. Nothing contained in this
document nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past,
present or the future performance of any Starpharma product.
Rules 4.7.3 and 4.10.3
Appendix 4G
Key to Disclosures
Corporate Governance Council Principles and Recommendations
Name of entity
Starpharma Holdings Limited
ABN/ARBN
Financial year ended:
20 078 532 180
30 June 2023
Our corporate governance statement 1 for the period above can be found at: 2
☐
These pages of our
annual report:
☒
This URL on our
website:
http://www.starpharma.com/corporate_governance
The Corporate Governance Statement is accurate and up to date as at 24 August 2023 and has been
approved by the Board.
The annexure includes a key to where our corporate governance disclosures can be located. 3
Date:
24 August 2023
Name of authorised officer
authorising lodgement:
Justin Cahill
1 “Corporate governance statement” is defined in Listing Rule 19.12 to mean the statement referred to in Listing Rule 4.10.3 which
discloses the extent to which an entity has followed the recommendations set by the ASX Corporate Governance Council during
a particular reporting period.
Listing Rule 4.10.3 requires an entity that is included in the official list as an ASX Listing to include in its annual report either a
corporate governance statement that meets the requirements of that rule or the URL of the page on its website where such a
statement is located. The corporate governance statement must disclose the extent to which the entity has followed the
recommendations set by the ASX Corporate Governance Council during the reporting period. If the entity has not followed a
recommendation for any part of the reporting period, its corporate governance statement must separately identify that
recommendation and the period during which it was not followed and state its reasons for not following the recommendation and
what (if any) alternative governance practices it adopted in lieu of the recommendation during that period.
Under Listing Rule 4.7.4, if an entity chooses to include its corporate governance statement on its website rather than in its annual
report, it must lodge a copy of the corporate governance statement with ASX at the same time as it lodges its annual report with
ASX. The corporate governance statement must be current as at the effective date specified in that statement for the purposes of
Listing Rule 4.10.3.
Under Listing Rule 4.7.3, an entity must also lodge with ASX a completed Appendix 4G at the same time as it lodges its annual
report with ASX. The Appendix 4G serves a dual purpose. It acts as a key designed to assist readers to locate the governance
disclosures made by a listed entity under Listing Rule 4.10.3 and under the ASX Corporate Governance Council’s
recommendations. It also acts as a verification tool for listed entities to confirm that they have met the disclosure requirements of
Listing Rule 4.10.3.
The Appendix 4G is not a substitute for, and is not to be confused with, the entity's corporate governance statement. They serve
different purposes and an entity must produce each of them separately.
2 Tick whichever option is correct and then complete the page number(s) of the annual report, or the URL of the web page, where
your corporate governance statement can be found. You can, if you wish, delete the option which is not applicable.
3 Throughout this form, where you are given two or more options to select, you can, if you wish, delete any option which is not
applicable and just retain the option that is applicable. If you select an option that includes “OR” at the end of the selection and
you delete the other options, you can also, if you wish, delete the “OR” at the end of the selection.
See notes 4 and 5 below for further instructions on how to complete this form.
ASX Listing Rules Appendix 4G (current at 17/7/2020)
Page 1
Appendix 4G
Key to Disclosures Corporate Governance Council Principles and Recommendations
ANNEXURE – KEY TO CORPORATE GOVERNANCE DISCLOSURES
Corporate Governance Council recommendation
Where a box below is ticked, 4 we have followed the
recommendation in full for the whole of the period above. We
have disclosed this in our Corporate Governance Statement
which is located at
http://www.starpharma.com/corporate_governance:
Where a box below is ticked, we have NOT followed the
recommendation in full for the whole of the period above. Our
reasons for not doing so are: 5
PRINCIPLE 1 – LAY SOLID FOUNDATIONS FOR MANAGEMENT AND OVERSIGHT
1.1
1.2
1.3
A listed entity should have and disclose a board charter setting
out:
(a) the respective roles and responsibilities of its board and
management; and
(b) those matters expressly reserved to the board and those
delegated to management.
☒
-
We have disclosed this information in our Corporate Governance
Statement under the heading ‘Responsibilities of the Board’.
We have disclosed a copy of our Board Charter at:
http://www.starpharma.com/corporate_governance.
A listed entity should:
(a) undertake appropriate checks before appointing a director or
senior executive or putting someone forward for election as
a director; and
(b) provide security holders with all material information in its
possession relevant to a decision on whether or not to elect
or re-elect a director.
☒
A listed entity should have a written agreement with each director
and senior executive setting out the terms of their appointment.
☒
-
We have disclosed this information in our Corporate Governance
Statement under the heading ‘Director/Senior Management
appointment and director election’.
-
We have disclosed this information in our Corporate Governance
Statement under the heading ‘Written agreements with Directors and
Senior Executives’.
Tick the box in this column only if you have followed the relevant recommendation in full for the whole of the period above. Where the recommendation has a disclosure obligation attached, you must insert
the location where that disclosure has been made, where indicated by the line with “insert location” underneath. If the disclosure in question has been made in your corporate governance statement, you
need only insert “our corporate governance statement”. If the disclosure has been made in your annual report, you should insert the page number(s) of your annual report (eg “pages 10-12 of our annual
report”). If the disclosure has been made on your website, you should insert the URL of the web page where the disclosure has been made or can be accessed (eg “www.entityname.com.au/corporate
governance/charters/”).
4
5
If you have followed all of the Council’s recommendations in full for the whole of the period above, you can, if you wish, delete this column from the form and re-format it.
ASX Listing Rules Appendix 4G (current at 17/7/2020)
Page 2
Appendix 4G
Key to Disclosures Corporate Governance Council Principles and Recommendations
Corporate Governance Council recommendation
Where a box below is ticked, 4 we have followed the
recommendation in full for the whole of the period above. We
have disclosed this in our Corporate Governance Statement
which is located at
http://www.starpharma.com/corporate_governance:
Where a box below is ticked, we have NOT followed the
recommendation in full for the whole of the period above. Our
reasons for not doing so are: 5
1.4
☒
-
1.5
The company secretary of a listed entity should be accountable
directly to the board, through the chair, on all matters to do with
the proper functioning of the board.
A listed entity should:
(a) have and disclose a diversity policy;
(b) through its board or a committee of the board set
measurable objectives for achieving gender diversity in the
composition of its board, senior executives and workforce
generally; and
(c) disclose in relation to each reporting period:
(1) the measurable objectives set for that period to
achieve gender diversity;
(2) the entity’s progress towards achieving those
objectives; and
(3) either:
(A) the respective proportions of men and women
on the board, in senior executive positions and
across the whole workforce (including how the
entity has defined “senior executive” for these
purposes); or
(B) if the entity is a “relevant employer” under the
Workplace Gender Equality Act, the entity’s
most recent “Gender Equality Indicators”, as
defined in and published under that Act.
If the entity was in the S&P / ASX 300 Index at the
commencement of the reporting period, the measurable objective
for achieving gender diversity in the composition of its board
should be to have not less than 30% of its directors of each
gender within a specified period.
ASX Listing Rules Appendix 4G (current at 17/7/2020)
We have disclosed this information in our Corporate Governance
Statement under the heading ‘Responsibilities of the Company
Secretary’.
This is reflected in our Board Charter located at:
http://www.starpharma.com/corporate_governance.
☒
-
We have disclosed this information in our Corporate Governance
Statement under the heading ‘Diversity objectives and achievement’.
We have disclosed a copy of our Diversity Policy at:
http://www.starpharma.com/corporate_governance.
We have disclosed the information referred to in paragraph (c) in our
Corporate Governance Statement under the heading ‘Diversity
objectives and achievement’.
Page 3
Appendix 4G
Key to Disclosures Corporate Governance Council Principles and Recommendations
Corporate Governance Council recommendation
Where a box below is ticked, 4 we have followed the
recommendation in full for the whole of the period above. We
have disclosed this in our Corporate Governance Statement
which is located at
http://www.starpharma.com/corporate_governance:
Where a box below is ticked, we have NOT followed the
recommendation in full for the whole of the period above. Our
reasons for not doing so are: 5
1.6
☒
-
1.7
A listed entity should:
(a) have and disclose a process for periodically evaluating the
performance of the board, its committees and individual
directors; and
(b) disclose for each reporting period whether a performance
evaluation has been undertaken in accordance with that
process during or in respect of that period.
A listed entity should:
(a) have and disclose a process for evaluating the performance
of its senior executives at least once every reporting period;
and
(b) disclose for each reporting period whether a performance
evaluation has been undertaken in accordance with that
process during or in respect of that period.
ASX Listing Rules Appendix 4G (current at 17/7/2020)
We have disclosed the evaluation process referred to in paragraph
(a) in our Corporate Governance Statement under the heading
‘Board, committee and director performance’.
We have disclosed in our Corporate Governance Statement that a
performance evaluation was undertaken in accordance with that
process during the reporting period.
☒
-
We have disclosed the evaluation process referred to in paragraph
(a) in our Corporate Governance Statement under the heading ‘CEO
and senior executive performance’.
We have disclosed in our Corporate Governance Statement that a
performance evaluation was undertaken in accordance with the
process during the reporting.
Page 4
Appendix 4G
Key to Disclosures Corporate Governance Council Principles and Recommendations
Corporate Governance Council recommendation
Where a box below is ticked, 4 we have followed the
recommendation in full for the whole of the period above. We
have disclosed this in our Corporate Governance Statement
which is located at
http://www.starpharma.com/corporate_governance:
Where a box below is ticked, we have NOT followed the
recommendation in full for the whole of the period above. Our
reasons for not doing so are: 5
PRINCIPLE 2 - STRUCTURE THE BOARD TO BE EFFECTIVE AND ADD VALUE
2.1
2.2
2.3
The board of a listed entity should:
(a) have a nomination committee which:
(1) has at least three members, a majority of whom are
independent directors; and
(2) is chaired by an independent director,
and disclose:
(3) the charter of the committee;
(4) the members of the committee; and
(5) as at the end of each reporting period, the number
of times the committee met throughout the period
and the individual attendances of the members at
those meetings; or
(b) if it does not have a nomination committee, disclose that
fact and the processes it employs to address board
succession issues and to ensure that the board has the
appropriate balance of skills, knowledge, experience,
independence and diversity to enable it to discharge its
duties and responsibilities effectively.
☒
A listed entity should have and disclose a board skills matrix
setting out the mix of skills that the board currently has or is
looking to achieve in its membership.
☒
A listed entity should disclose:
(a) the names of the directors considered by the board to be
independent directors;
(b) if a director has an interest, position, affiliation or
relationship of the type described in Box 2.3 but the board
is of the opinion that it does not compromise the
independence of the director, the nature of the interest,
position or relationship in question and an explanation of
why the board is of that opinion; and
(c) the length of service of each director.
☒
ASX Listing Rules Appendix 4G (current at 17/7/2020)
-
Starpharma complies with paragraph (a), (1) and (2). We have
disclosed details of the Remuneration and Nomination Committee in
our Corporate Governance Statement under the heading
‘Remuneration and Nomination Committee’.
We have disclosed a copy of the Remuneration and Nomination
Committee Charter, which is available at:
http://www.starpharma.com/corporate_governance.
The information referred to in paragraph (4) is disclosed in our
Corporate Governance Statement under the heading ‘Remuneration
and Nomination Committee’.
The information referred to in paragraph (5) is disclosed in our
Directors’ Report (refer to Starpharma’s Annual Report 2023, under
the heading ‘Meetings of Directors’).
-
We have disclosed our board skills matrix in our Corporate
Governance Statement under the heading ‘Board skills’.
-
We have disclosed the names of the directors considered by the
board to be independent directors (paragraph (a)) and the length of
their service (paragraph (c)) in Starpharma’s Annual Report 2023,
under the heading ‘Director/senior management appointment and
director election’.
We have disclosed the information referred to in paragraph (b) in our
Corporate Governance Statement under the heading ‘Directors
Independence’.
Page 5
Appendix 4G
Key to Disclosures Corporate Governance Council Principles and Recommendations
Corporate Governance Council recommendation
Where a box below is ticked, 4 we have followed the
recommendation in full for the whole of the period above. We
have disclosed this in our Corporate Governance Statement
which is located at
http://www.starpharma.com/corporate_governance:
Where a box below is ticked, we have NOT followed the
recommendation in full for the whole of the period above. Our
reasons for not doing so are: 5
2.4
A majority of the board of a listed entity should be independent
directors.
☒
-
The chair of the board of a listed entity should be an
independent director and, in particular, should not be the same
person as the CEO of the entity.
☒
A listed entity should have a program for inducting new
directors and for periodically reviewing whether there is a need
for existing directors to undertake professional development to
maintain the skills and knowledge needed to perform their role
as directors effectively.
☒
2.5
2.6
We have disclosed this information in our Corporate Governance
Statement under the heading ‘Directors’ independence’.
-
We have disclosed this information in our Corporate Governance
Statement under the heading ‘Chairman and Chief Executive Officer
(CEO)’.
-
We have disclosed this information in our Corporate Governance
Statement under the headings ‘Board skills’ and ‘Director induction
and professional development’.
PRINCIPLE 3 – INSTIL A CULTURE OF ACTING LAWFULLY, ETHICALLY AND RESPONSIBLY
3.1
A listed entity should articulate and disclose its values.
☒
-
We have disclosed this information in our Corporate Governance
Statement under the heading ‘Values’ and in our Code of Conduct
Policy, available at:
http://www.starpharma.com/corporate_governance.
3.2
3.3
A listed entity should:
(a) have and disclose a code of conduct for its directors,
senior executives and employees; and
(b) ensure that the board or a committee of the board is
informed of any material breaches of that code.
☒
A listed entity should:
(a) have and disclose a whistleblower policy; and
(b) ensure that the board or a committee of the board is
informed of any material incidents reported under that
policy.
☒
ASX Listing Rules Appendix 4G (current at 17/7/2020)
-
We have disclosed this information in our Corporate Governance
Statement under the heading ‘Code of conduct’.
We have disclosed our Code of Conduct Policy at:
http://www.starpharma.com/corporate_governance.
-
We have disclosed this information in our Corporate Governance
Statement under the heading ‘Whistleblower policy’.
We have disclosed our Whistleblower Policy at:
http://www.starpharma.com/corporate_governance.
Page 6
Appendix 4G
Key to Disclosures Corporate Governance Council Principles and Recommendations
Corporate Governance Council recommendation
Where a box below is ticked, 4 we have followed the
recommendation in full for the whole of the period above. We
have disclosed this in our Corporate Governance Statement
which is located at
http://www.starpharma.com/corporate_governance:
Where a box below is ticked, we have NOT followed the
recommendation in full for the whole of the period above. Our
reasons for not doing so are: 5
3.4
☒
-
A listed entity should:
(a) have and disclose an anti-bribery and corruption policy;
and
(b) ensure that the board or committee of the board is
informed of any material breaches of that policy.
ASX Listing Rules Appendix 4G (current at 17/7/2020)
We have disclosed this information in our Corporate Governance
Statement under the heading ‘Anti-bribery and corruption policy’.
We have disclosed our Anti-bribery and Corruption Policy at:
http://www.starpharma.com/corporate_governance.
Page 7
Appendix 4G
Key to Disclosures Corporate Governance Council Principles and Recommendations
Corporate Governance Council recommendation
Where a box below is ticked, 4 we have followed the
recommendation in full for the whole of the period above. We
have disclosed this in our Corporate Governance Statement
which is located at
http://www.starpharma.com/corporate_governance:
Where a box below is ticked, we have NOT followed the
recommendation in full for the whole of the period above. Our
reasons for not doing so are: 5
PRINCIPLE 4 – SAFEGUARD THE INTEGRITY OF CORPORATE REPORTS
4.1
4.2
The board of a listed entity should:
(a) have an audit committee which:
(1) has at least three members, all of whom are nonexecutive directors and a majority of whom are
independent directors; and
(2) is chaired by an independent director, who is not
the chair of the board,
and disclose:
(3) the charter of the committee;
(4) the relevant qualifications and experience of the
members of the committee; and
(5) in relation to each reporting period, the number of
times the committee met throughout the period and
the individual attendances of the members at those
meetings; or
(b) if it does not have an audit committee, disclose that fact
and the processes it employs that independently verify
and safeguard the integrity of its corporate reporting,
including the processes for the appointment and removal
of the external auditor and the rotation of the audit
engagement partner.
The board of a listed entity should, before it approves the
entity’s financial statements for a financial period, receive from
its CEO and CFO a declaration that, in their opinion, the
financial records of the entity have been properly maintained
and that the financial statements comply with the appropriate
accounting standards and give a true and fair view of the
financial position and performance of the entity and that the
opinion has been formed on the basis of a sound system of risk
management and internal control which is operating effectively.
ASX Listing Rules Appendix 4G (current at 17/7/2020)
☒
-
Starpharma complies with paragraph (a), (1) and (2). We have
disclosed details of the Audit and Risk Committee in our Corporate
Governance Statement under the heading ‘Audit and Risk
Committee’.
We have disclosed a copy of the Audit and Risk Committee Charter
at:
http://www.starpharma.com/corporate_governance.
The information referred to in paragraph (4) is in our Directors’
Report (refer to Starpharma’s Annual Report 2023, under the
heading ‘Information on Directors’).
The information referred to in paragraph (5) is in our Directors’
Report (refer to Starpharma’s Annual Report 2023, under the
heading ‘Meetings of Directors’).
☒
-
We have disclosed this information in our Corporate Governance
Statement under the heading ‘CEO and CFO declarations for
financial statements’.
Page 8
Appendix 4G
Key to Disclosures Corporate Governance Council Principles and Recommendations
Corporate Governance Council recommendation
Where a box below is ticked, 4 we have followed the
recommendation in full for the whole of the period above. We
have disclosed this in our Corporate Governance Statement
which is located at
http://www.starpharma.com/corporate_governance:
Where a box below is ticked, we have NOT followed the
recommendation in full for the whole of the period above. Our
reasons for not doing so are: 5
4.3
☒
-
A listed entity should disclose its process to verify the integrity
of any periodic corporate report it releases to the market that is
not audited or reviewed by an external auditor.
We have disclosed this information in our Corporate Governance
Statement under the heading ‘Verification process for unaudited
reports’.
PRINCIPLE 5 – MAKE TIMELY AND BALANCED DISCLOSURE
5.1
5.2
5.3
A listed entity should have and disclose a written policy for
complying with its continuous disclosure obligations under
listing rule 3.1.
☒
A listed entity should ensure that its board receives copies of all
material market announcements promptly after they have been
made.
☒
A listed entity that gives a new and substantive investor or
analyst presentation should release a copy of the presentation
materials on the ASX Market Announcements Platform ahead
of the presentation.
☒
-
We have disclosed this information in our Corporate Governance
Statement under the heading ‘Continuous disclosure policy’.
We have disclosed our continuous disclosure compliance policy at:
http://www.starpharma.com/corporate_governance.
-
We have disclosed this information in our Corporate Governance
Statement under the heading ‘Board promptly receives material
announcements’.
-
We have disclosed this information in our Corporate Governance
Statement under the heading ‘Investor presentations’.
PRINCIPLE 6 – RESPECT THE RIGHTS OF SECURITY HOLDERS
6.1
6.2
A listed entity should provide information about itself and its
governance to investors via its website.
A listed entity should have an investor relations program that
facilitates effective two-way communication with investors.
ASX Listing Rules Appendix 4G (current at 17/7/2020)
☒
-
We have disclosed this information in our Corporate Governance
Statement under the heading ‘Information on website’.
We have disclosed information about us and our governance on our
website at:
http://www.starpharma.com/ and
http://www.starpharma.com/corporate_governance.
☒
-
We have disclosed this information in our Corporate Governance
Statement under the heading ‘Communication with investors’.
Page 9
Appendix 4G
Key to Disclosures Corporate Governance Council Principles and Recommendations
Corporate Governance Council recommendation
Where a box below is ticked, 4 we have followed the
recommendation in full for the whole of the period above. We
have disclosed this in ou
Share your feedback
Discover